Science

Vivek Subbiah: Exploring the role of ctDNA Clearance as a Predictive Biomarker in Solid Tumors

Vivek Subbiah/LinkedIn

Apr 8, 2025, 15:46

Vivek Subbiah: Exploring the role of ctDNA Clearance as a Predictive Biomarker in Solid Tumors

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a LinkedIn post about recent paper he and his colleagues authored:

“New paper alert! Pleased to share our paper.

A systematic review and meta-analysis exploring the role of “Circulating tumor DNA (ctDNA) clearance as a predictive biomarker for solid tumors treated with neoadjuvant immune-checkpoint inhibitors.”

Key takeaways:

1. Lack of ctDNA clearance may indicate patients unlikely to achieve pathologic complete response
2. However, the predictive power is limited by low specificity.

Kudos to the research team led by Giuseppe Curigliano and an amazing co-author team.

Read the full paper here.”

Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

Authors: C. Valenza, Vivek Subbiah, Giuseppe Curigliano et al.

Vivek Subbiah

A.H. Partridge C. Cremolini C. Valenza cancer D. Gritsch Dario Trapani E.F. Saldanha F. Conforti Giuseppe Curigliano H. Ortiz H.A. Parsons J. Mateo OncoDaily Oncology P De Placido S. Peters Vivek Subbiah Y. Gong

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial

John Cena Announces He Overcame Skin Cancer Twice, Advocates for Sun Safety

William N. Hait to Receive 2025 AACR-Margaret Foti Award for Leadership in Cancer Research